Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV Infection

Authors:
  • JEJanie Eddy
    Janie Eddy
  • JFJudy Falloon
    Judy Falloon
  • RMRobert F. Murphy
    Robert F. Murphy
  • HMHoward Moss
    Howard Moss
  • PWPam Wolters
    Pam Wolters
  • PBPim Brouwers
    Pim Brouwers
  • PJPaul Jarosinski
    Paul Jarosinski
  • MRMarc Rubin
    Marc Rubin
  • SBSamuel Broder
    Samuel Broder
  • RYRobert Yarchoan
    Robert Yarchoan

Abstract
To produce concentrations of zidovudine (AZT) in plasma and cerebrospinal fluid that would provide constant inhibition of the replication of human immunodeficiency virus (HIV), we gave AZT by continuous intravenous infusion to 21 children ranging in age from 14 months to 12 years who had acquired HIV infection through transfusions or perinatally. All patients were symptomatic before AZT treatment (Class P2 of the Centers for Disease Control); 13 (62 percent) had evidence of neurodevelopmental abnormalities. The mean CD4/CD8 ratio was 0.18; 11 patients had CD4 counts below 0.2X109 per liter.

This publication has 32 references indexed in Scilit: